From the Journals

Trial of mesh vs. hysterectomy for prolapse yields inconclusive results


 

FROM JAMA

A role for mesh?

“The report ... by Nager and colleagues is particularly timely and important,” Cynthia A. Brincat, MD, PhD, wrote in an accompanying editorial. Dr. Brincat is affiliated with the division of female pelvic medicine and reconstructive surgery at Rush Medical College, Chicago.

Although the mesh exposures, granulation tissue, or suture exposures during the trial did not require reoperation, “management of these adverse events was not described,” the editorialist noted. “Clinically important differences could exist between the management of these reported adverse events.”

Based on the findings, gynecologic surgeons “will need to reconsider several important questions regarding the repair of pelvic organ prolapse. For instance, is hysterectomy a necessary component for the repair? What is the role of mesh, and can its use reduce the use of otherwise unnecessary procedures (i.e., hysterectomy) without increasing risk to patients?” she wrote. Other questions center on what constitutes operative failure and how surgeons should augment prolapse repair.

“This study also provides a potential new and well-defined role for the use of mesh in pelvic prolapse surgery, with no significant difference, and perhaps some benefit (i.e., no hysterectomy), compared with a native tissue repair,” Dr. Brincat wrote. “The study also provides useful information for shared decision-making discussions between patients and gynecologic surgeons with respect to selection of procedures and use of mesh for treatment of women with symptomatic uterovaginal prolapse undergoing vaginal surgery.”

The trial was funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Institutes of Health Office of Research on Women’s Health. Boston Scientific provided support through an unrestricted grant. One author reported stock ownership in a medical device company, and others reported grants from medical device companies outside the submitted work. Dr. Brincat reported no conflicts of interest.

SOURCES: Nager CW et al. JAMA. 2019 Sep 17;322(11):1054-65; Brincat CA. JAMA. 2019 Sep 17;322(11):1047-8.

Pages

Recommended Reading

Diagnosis, treatment, and prevention of ovarian remnant syndrome
MDedge ObGyn
Lymphoma risk prompts FDA recall of Allergan’s textured breast implants
MDedge ObGyn
Office hysteroscopic evaluation of postmenopausal bleeding
MDedge ObGyn
Morcellation use in gynecologic surgery: Current clinical recommendations and cautions
MDedge ObGyn
Product Update: Osphena’s NDA, new hysteroscope, TempSure RF technology, Resilient stirrup covers
MDedge ObGyn
Predictive model estimates likelihood of failing induction of labor in obese patients
MDedge ObGyn
Minimally invasive surgery for cervical cancer: Is surgeon volume a factor?
MDedge ObGyn
Native tissue repair of POP: Surgical techniques to improve outcomes
MDedge ObGyn
Embryologic development of the external genitalia as it relates to vaginoplasty for the transgender woman
MDedge ObGyn
Native tissue repair of POP: Apical suspension, anterior repair, and posterior repair
MDedge ObGyn